Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 47

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 47
---
 of another party, we could be required to pay significant
damages or license fees to such party and/or cease production, marketing and distribution of those products. Litigation may also be necessary
to defend infringement claims of third parties or to enforce patent rights we hold or to protect trade secrets or techniques we own.

We also rely on trade secrets
and other unpatented proprietary technology. There can be no assurances that we can meaningfully protect our rights in our unpatented
proprietary technology or that others will not independently develop substantially equivalent proprietary products or processes or otherwise
gain access to our proprietary technology. We seek to protect our trade secrets and proprietary know-how, in part, with confidentiality
agreements with employees and consultants that include customary intellectual property assignment obligations. There can be no assurances,
however, that the agreements will not be breached, adequate remedies for any breach would be available or competitors will not discover
our trade secrets or independently develop comparable intellectual property.

Obtaining and maintaining patent protection depends on compliance with various procedures, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.

The USPTO, and various foreign
governmental patent agencies require compliance with a number of procedures, documentary, fee payment and other similar provisions during
the patent application process. In addition, periodic maintenance fees, renewal fees, annuity fees and various other government fees on
issued patents often must be paid to the USPTO and foreign patent agencies over the lifetime of the patent and/or applications and any
patent rights we may obtain in the future. While an unintentional lapse of a patent or patent application can in many cases be cured by
payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result
in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.
Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure
to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents.
If we fail to maintain the patents and patent applications covering our products, we may not be able to stop a competitor from marketing
products that are the same as or similar to our products, which would have a material adverse effect on our business.

Although we are not presently a party to